Clinical Trials Browser

Hemangiosarcoma × pembrolizumab × 90 days × Clear all

Hemangiosarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms